BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 15380349)

  • 1. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia.
    Hogge DE; Feuring-Buske M; Gerhard B; Frankel AE
    Leuk Res; 2004 Nov; 28(11):1221-6. PubMed ID: 15380349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
    Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
    Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors.
    Feuring-Buske M; Gerhard B; Cashman J; Humphries RK; Eaves CJ; Hogge DE
    Leukemia; 2003 Apr; 17(4):760-3. PubMed ID: 12682634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A real-time quantitative RT-PCR assay for monitoring DEK-CAN fusion transcripts arising from translocation t(6;9) in acute myeloid leukemia.
    Østergaard M; Stentoft J; Hokland P
    Leuk Res; 2004 Nov; 28(11):1213-5. PubMed ID: 15380347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
    Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
    Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.
    Black JH; McCubrey JA; Willingham MC; Ramage J; Hogge DE; Frankel AE
    Leukemia; 2003 Jan; 17(1):155-9. PubMed ID: 12529673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
    Perentesis JP; Gunther R; Waurzyniak B; Yanishevski Y; Myers DE; Ek O; Messinger Y; Shao Y; Chelstrom LM; Schneider E; Evans WE; Uckun FM
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2217-27. PubMed ID: 9815618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.
    Urieto JO; Liu T; Black JH; Cohen KA; Hall PD; Willingham MC; Pennell LK; Hogge DE; Kreitman RJ; Frankel AE
    Protein Expr Purif; 2004 Jan; 33(1):123-33. PubMed ID: 14680969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice.
    Hall PD; Kreitman RJ; Willingham MC; Frankel AE
    Toxicol Appl Pharmacol; 1998 May; 150(1):91-7. PubMed ID: 9630457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells.
    Feuring-Buske M; Frankel A; Gerhard B; Hogge D
    Exp Hematol; 2000 Dec; 28(12):1390-400. PubMed ID: 11146161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia.
    Hall PD; Willingham MC; Kreitman RJ; Frankel AE
    Leukemia; 1999 Apr; 13(4):629-33. PubMed ID: 10214872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors.
    Hogge DE; Yalcintepe L; Wong SH; Gerhard B; Frankel AE
    Clin Cancer Res; 2006 Feb; 12(4):1284-91. PubMed ID: 16489085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials.
    Frankel AE; Ramage J; Latimer A; Feely T; Delatte S; Hall P; Tagge E; Kreitman R; Willingham M
    Protein Expr Purif; 1999 Jun; 16(1):190-201. PubMed ID: 10336877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system for biotherapy of GMCSF-receptor positive hematologic malignancies.
    Williams MD; Rostovtsev A; Narla RK; Uckun FM
    Protein Expr Purif; 1998 Jul; 13(2):210-21. PubMed ID: 9675065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
    Perentesis JP; Waddick KG; Bendel AE; Shao Y; Warman BE; Chandan-Langlie M; Uckun FM
    Clin Cancer Res; 1997 Mar; 3(3):347-55. PubMed ID: 9815691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia.
    Hall PD; Virella G; Willoughby T; Atchley DH; Kreitman RJ; Frankel AE
    Clin Immunol; 2001 Aug; 100(2):191-7. PubMed ID: 11465948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells.
    Kim CN; Bhalla K; Kreitman RJ; Willingham MC; Hall P; Tagge EP; Jia T; Frankel AE
    Leuk Res; 1999 Jun; 23(6):527-38. PubMed ID: 10374846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.
    Lin JM; Li B; Rimmer E; VanRoey M; Jooss K
    Exp Hematol; 2008 Mar; 36(3):319-28. PubMed ID: 18279719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experimental study of cord blood plasma enhancing the anti-leukemia effect of Ara-C].
    Zhang X; Chen Y; Wang X
    Zhonghua Xue Ye Xue Za Zhi; 1999 May; 20(5):229-31. PubMed ID: 11601208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fresh frozen plasma and platelet concentrates may increase plasma anti-diphtheria toxin IgG concentrations: Implications for diphtheria fusion protein therapy.
    Hall PD; Sinha D; Frankel AE
    Cancer Immunol Immunother; 2006 Aug; 55(8):928-32. PubMed ID: 16645883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.